CR6706A - PIRIDO (2,3-D) PIRIMIDIN-2-7-KINASE INHIBITING DIAMINS - Google Patents

PIRIDO (2,3-D) PIRIMIDIN-2-7-KINASE INHIBITING DIAMINS

Info

Publication number
CR6706A
CR6706A CR6706A CR6706A CR6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A CR 6706 A CR6706 A CR 6706A
Authority
CR
Costa Rica
Prior art keywords
compounds
substituted
unsubstituted
pirido
diamins
Prior art date
Application number
CR6706A
Other languages
Spanish (es)
Inventor
Myra Dobrusin Ellen
Prasad Venkata Nagendra Josyula Vara
John Booth Richard
Joseph Mcnamara Dennis
Laurence Toogood Peter
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6706A publication Critical patent/CR6706A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Consiste en compuestos de formula en la cual R2, R7, R13, y R15, son independientemente, hidrogeno o alquilo inferior sustituido o sin sustituir, alquenilo inferior sustituido o sin sustituir, alquinilo inferior sustituido o sin sustituir, o bien -(CH2) nR112 sustituido o sin sustituir y otros compuestos. Estos compuestos y sus composiciones farmaceuticas son utiles para tratar trastornos proliferativos celulares, tales como cancer y restenosis. Estos compuestos son potentes inhibidores de cdks y de cinasas mediadas por factor de crecimiento.It consists of compounds of formula in which R2, R7, R13, and R15, are independently substituted or unsubstituted hydrogen or lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, or - (CH2) nR112 substituted or unsubstituted and other compounds. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor-mediated kinases.

CR6706A 2000-01-25 2002-07-17 PIRIDO (2,3-D) PIRIMIDIN-2-7-KINASE INHIBITING DIAMINS CR6706A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25

Publications (1)

Publication Number Publication Date
CR6706A true CR6706A (en) 2005-04-04

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6706A CR6706A (en) 2000-01-25 2002-07-17 PIRIDO (2,3-D) PIRIMIDIN-2-7-KINASE INHIBITING DIAMINS

Country Status (34)

Country Link
EP (1) EP1254137A1 (en)
JP (1) JP4047010B2 (en)
KR (1) KR20020065939A (en)
CN (1) CN1395578A (en)
AP (1) AP2002002586A0 (en)
AR (1) AR030044A1 (en)
AU (1) AU2542501A (en)
BG (1) BG106850A (en)
BR (1) BR0107751A (en)
CA (1) CA2397961C (en)
CO (1) CO5261549A1 (en)
CR (1) CR6706A (en)
CZ (1) CZ20022475A3 (en)
DZ (1) DZ3266A1 (en)
EA (1) EA200200643A1 (en)
EE (1) EE200200405A (en)
GT (1) GT200100016A (en)
HN (1) HN2001000013A (en)
HU (1) HUP0204141A3 (en)
IL (1) IL150545A0 (en)
IS (1) IS6443A (en)
MA (1) MA26868A1 (en)
MX (1) MXPA02007221A (en)
NO (1) NO20023527L (en)
OA (1) OA12161A (en)
PA (1) PA8510701A1 (en)
PE (1) PE20011066A1 (en)
PL (1) PL356802A1 (en)
SK (1) SK10632002A3 (en)
SV (1) SV2002000294A (en)
TN (1) TNSN01014A1 (en)
WO (1) WO2001055147A1 (en)
YU (1) YU50402A (en)
ZA (1) ZA200205879B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN100525768C (en) 2000-10-23 2009-08-12 史密丝克莱恩比彻姆公司 Novel compounds
PE20030008A1 (en) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co DUAL INHIBITORS OF PDE 7 AND PDE 4
KR20040103972A (en) 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 Novel Compounds
JP2006508997A (en) * 2002-11-28 2006-03-16 シエーリング アクチエンゲゼルシャフト Chk-, Pdk- and Akt-inhibiting pyrimidines, their preparation and use as pharmaceuticals
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
CA2579406A1 (en) * 2004-09-21 2006-03-30 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as protein kinase inhibitors
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
PE20061193A1 (en) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVATIVES OF 3,4-DIHYDROPYRIMIDO [4,5-d] PYRIMIDIN-2- [1H] -0NA AS KINASE INHIBITORS p38
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
ES2336603T3 (en) * 2005-07-21 2010-04-14 F. Hoffmann-La Roche Ag PIRIDO COMPOUNDS (2,3-D) PYRIMIDINE-2,4-DIAMINE AS INHIBITORS OF PTP1B.
WO2007021795A2 (en) * 2005-08-09 2007-02-22 Irm Llc Compounds and compositions as protein kinase inhibitors
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (en) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co MAPK/ERK Kinase Inhibitors
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CN102216299B (en) * 2008-12-01 2015-02-11 默克专利有限公司 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
US9815847B2 (en) 2013-03-14 2017-11-14 Icahn School Of Medicine At Mount Sinai Pyrimidine compounds as kinase inhibitors
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (en) * 2014-09-02 2016-11-02 한국원자력의학원 Pyrimidine derivatives having anti-cancer effect, combination therapeutic effect with radiation, and anti-diabetic effect, and PPAR activity, and medical use thereof
CN107286180B (en) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 Heteropyridopyrimidinone derivatives as CDK inhibitors and their applications
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
PL181893B1 (en) * 1994-11-14 2001-10-31 Warner Lambert Co Pyrimidine and naphthyridine derivative compounds and a pharmaceutical preparation containing them EN EN EN
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
TR200003429T2 (en) * 1998-05-26 2001-07-23 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as cellular growth inhibitors.

Also Published As

Publication number Publication date
SK10632002A3 (en) 2003-06-03
HUP0204141A2 (en) 2003-04-28
SV2002000294A (en) 2002-07-16
GT200100016A (en) 2001-10-19
EA200200643A1 (en) 2002-12-26
ZA200205879B (en) 2003-09-29
AP2002002586A0 (en) 2002-09-30
PL356802A1 (en) 2004-07-12
KR20020065939A (en) 2002-08-14
IL150545A0 (en) 2003-02-12
EP1254137A1 (en) 2002-11-06
OA12161A (en) 2006-05-08
NO20023527D0 (en) 2002-07-24
AU2542501A (en) 2001-08-07
BR0107751A (en) 2002-11-12
DZ3266A1 (en) 2001-08-02
CA2397961C (en) 2008-08-26
CA2397961A1 (en) 2001-08-02
HN2001000013A (en) 2001-06-18
HUP0204141A3 (en) 2005-03-29
WO2001055147A1 (en) 2001-08-02
JP2003523357A (en) 2003-08-05
NO20023527L (en) 2002-09-10
AR030044A1 (en) 2003-08-13
MA26868A1 (en) 2004-12-20
YU50402A (en) 2005-11-28
PE20011066A1 (en) 2001-10-22
CZ20022475A3 (en) 2003-03-12
IS6443A (en) 2002-06-25
CN1395578A (en) 2003-02-05
JP4047010B2 (en) 2008-02-13
CO5261549A1 (en) 2003-03-31
TNSN01014A1 (en) 2005-11-10
PA8510701A1 (en) 2002-12-11
EE200200405A (en) 2003-12-15
MXPA02007221A (en) 2002-11-29
BG106850A (en) 2003-02-28

Similar Documents

Publication Publication Date Title
CR6706A (en) PIRIDO (2,3-D) PIRIMIDIN-2-7-KINASE INHIBITING DIAMINS
CR6736A (en) 5-ALQUILPIRIDO [2,3-D [PIRIDINES AS INHIBITORS OF TYPOSINE KINASA
BRPI0507644A (en) pyrazolopyrimidines as cyclin-dependent kinase inhibitors
ES2192877T3 (en) 4-ALQUENIL (AND ALQUINIL) OXINDOLS AS INHIBITORS OF CYCLINE-DEPENDENT KINASES, IN PARTICULAR CDK2.
TW200407311A (en) N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
GEP20125658B (en) Imidazotriazines and imidazo pyrimidines as kinase inhibitors
MY139355A (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
IL173348A0 (en) Thienopyridine and furopyridine kinase inhibitors
TW200510380A (en) Mitotic kinesin inhibitors
CR9219A (en) TRIAZOL DERIVATIVES REPLACED AS AN OXITOCINE ANTAGONISTS
YU61402A (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
UY27234A1 (en) NOVELTY INHIBITORS OF TYROSINE KINASE
ECSP078062A (en) 1,4-DIHYDROPIRIDINE-CONDENSED HETEROCICLES, PROCESSES TO PREPARE THE SAME, USE AND COMPOSITIONS CONTAINING THEM
GEP20125368B (en) Kinase inhibitors
MXPA05011296A (en) Kinase inhibitor phosphonate conjugates.
BRPI0511975A (en) pyrazolopyrimidines
ATE554087T1 (en) NEW KINASE INHIBITORS
MXPA05013076A (en) Isoindolin-1-one compounds as kinase inhibitors.
TN2009000329A1 (en) 2-AMINO-5,7-DIHYDRO-6H-PYRROLO [3,4-d] -PYRIMIDINE DERIVATIVES AS INHBITORS OF HSP-90 FOR THE TREATMENT OF CANCER
MXPA05009151A (en) Heterocyclic kinase inhibitors.
CR9579A (en) THYROSINE KINASE INHIBITORS
PA8613001A1 (en) TRIAZOL DERIVATIVES REPLACED AS AN OXITOCINE ANTAGONISTS
ECSP034776A (en) INDOLINONES REPLACED IN POSITION 6, ITS PREPARATION AND ITS USE AS MEDICATIONS
AR026037A1 (en) INDOLINONES REPLACED IN POSITION 5, ITS PREPARATION AND ITS USE AS MEDICATIONS
DE60100539D1 (en) Tosylprolin-derivate als thymidylat-synthase inhibitoren

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)